Ceftolozane and tazobactam for the treatment of hospital acquired pneumonia

References

• Martin-Loeches I, Rodriguez AH, Torres A. New guidelines for hospital-acquired pneumonia/ventilator-associated pneumonia: USA vs. Europe. Curr Opin Crit Care. 2018;24:347–352. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30063491.
   PubMed Web of Science ®Google Scholar
• Tamma PD, Cosgrove SE, Maragakis LL. Combination therapy for treatment of infections with gram-negative bacteria. Clin Microbiol Rev. 2012;25:450–470.
   PubMed Web of Science ®Google Scholar
• Toda A, Ohki H, Yamanaka T, et al. Synthesis and SAR of novel parenteral anti-pseudomonal cephalosporins: discovery of FR264205. Bioorg Med Chem Lett. 2008;18:4849–4852. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0960894X08008627
   PubMed Web of Science ®Google Scholar
• Hong MC, Hsu DI, Bounthavong M. Ceftolozane/tazobactam: A novel antipseudomonal cephalosporin and β-lactamase-inhibitor combination. Infect Drug Resist Dove. 2013 [cited 2020 Jun 23];215–223. Available from: /pmc/articles/PMC3848746/?report=abstract.
   Google Scholar
• Moyá B, Zamorano L, Juan C, et al. Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2010;54:3933–3937. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20547785
   PubMed Web of Science ®Google Scholar
• Sader HS, Flamm RK, Streit JM, et al. Abstracts: 52nd interscience conference on antimicrobial agents and chemotherapy. Washington: American Society for Microbiology; 2012. Activity of novel antimicrobial ceftolozane/tazobactam tested against contempor.
   Google Scholar
• Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis. 2002;34:634–640. Available from: http://cid.oxfordjournals.org/content/34/5/634.abstract
   PubMed Web of Science ®Google Scholar
• Petraitis V, Petraitiene R, Naing E, et al. Ceftolozane-tazobactam in the treatment of experimental Pseudomonas aeruginosa pneumonia in persistently neutropenic rabbits: impact on strains with genetically defined mechanisms of resistance. Antimicrob Agents Chemother. 2019[cited 2020 Jun 23];63. Available from: https://pubmed.ncbi.nlm.nih.gov/31235620/.
   Web of Science ®Google Scholar
• Craig WA, Andes DR. In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum β-lactamases, in the thighs of neutropenic mice. Antimicrob Agents Chemother. 2013 [cited 2020 Jun 23];57:1577–1582. Available from: https://pubmed.ncbi.nlm.nih.gov/23274659/
   PubMed Web of Science ®Google Scholar
• Chandorkar G, Huntington JA, Gotfried MH, et al. Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects. J Antimicrob Chemother. 2012;67:2463–2469.
   PubMed Web of Science ®Google Scholar
• Xiao AJ, Miller BW, Huntington JA, et al. Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia. J Clin Pharmacol. 2016;56:56–66.
   PubMed Web of Science ®Google Scholar
• Kollef MH, Nováček M, Ü K, et al. Ceftolozane–tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2019;19:1299–1311.
   PubMed Web of Science ®Google Scholar
• Monogue ML, Pettit RS, Muhlebach M, et al. Population pharmacokinetics and safety of ceftolozane-tazobactam in adult cystic fibrosis patients admitted with acute pulmonary exacerbation. Antimicrob Agents Chemother. 2016;60:6578–6584.
   PubMed Web of Science ®Google Scholar
• Haidar G, Philips NJ, Shields RK, et al. Ceftolozane-tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: clinical effectiveness and evolution of resistance. Clin Infect Dis. 2017;65:110–120.
   PubMed Web of Science ®Google Scholar
• Munita JM, Aitken SL, Miller WR, et al. Multicenter evaluation of ceftolozane/tazobactam for serious infections caused by carbapenem-resistant Pseudomonas aeruginosa. Clin Infect Dis. 2017;65:158–161.
   PubMed Web of Science ®Google Scholar
• Fraile-Ribot PA, Cabot G, Mulet X, et al. Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa. J Antimicrob Chemother. 2018;73:658–663. Available from: https://academic.oup.com/jac/article/73/3/658/4629302
   PubMed Web of Science ®Google Scholar
• Gallagher JC, Satlin MJ, Elabor A, et al. Ceftolozane-tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: A multicenter study. Open Forum Infect Dis. 2018;5:1–5.
   Web of Science ®Google Scholar
• Merck Sharp & Dohme. ZERBAXA (ceftolozane and tazobactam) for injection. Full prescribing information. Whitehouse Station, NJ: Merck; 2015.
   Google Scholar
• Ge Y, Whitehouse MJ, Friedland I, et al. Pharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single- and multiple-dose intravenous infusions. Antimicrob Agents Chemother. 2010;54:3427–3431.
   PubMed Web of Science ®Google Scholar
• Miller B, Hershberger E, Benziger D, et al. Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses. Antimicrob Agents Chemother. 2012;56:3086–3091.
   PubMed Web of Science ®Google Scholar
• Chandorkar G, Xiao A, Mouksassi M-S, et al. Population pharmacokinetics of ceftolozane/tazobactam in healthy volunteers, subjects with varying degrees of renal function and patients with bacterial infections. J Clin Pharmacol. 2015;55:230–239.
   PubMed Web of Science ®Google Scholar
• Wooley M, Miller B, Krishna G, et al. Impact of renal function on the pharmacokinetics and safety of ceftolozane-tazobactam. Antimicrob Agents Chemother. 2014;58:2249–2255.
   PubMed Web of Science ®Google Scholar
• Hsu DI, Nguyen M, Nguyen L, et al. A multicentre study to evaluate the impact of timing of caspofungin administration on outcomes of invasive candidiasis in non-immunocompromised adult patients. J Antimicrob Chemother. 2010;65:1765–1770. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20554567
   PubMed Web of Science ®Google Scholar
• Natesan S, Pai MP, Lodise TP. Determination of alternative ceftolozane/tazobactam dosing regimens for patients with infections due to Pseudomonas aeruginosa with MIC values between 4 and 32 mg/L. J Antimicrob Chemother. 2017;72:2813–2816. Available from: http://academic.oup.com/jac/article/72/10/2813/4002757.
   PubMed Web of Science ®Google Scholar
• Carvalhaes CG, Castanheira M, Sader HS, et al. Antimicrobial activity of ceftolozane–tazobactam tested against gram-negative contemporary (2015–2017) isolates from hospitalized patients with pneumonia in US medical centers. Diagn Microbiol Infect Dis. 2019;94:93–102. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0732889318304255
   PubMed Web of Science ®Google Scholar
• Farrell DJ, Sader HS, Flamm RK, et al. Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012). Int J Antimicrob Agents. 2014;43:533–539. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0924857914000685
   PubMed Web of Science ®Google Scholar
• Sutherland CA, Nicolau DP. Potency of parenteral antimicrobials including ceftolozane/tazobactam against nosocomial respiratory tract pathogens: considerations for empiric and directed therapy. J Thorac Dis. 2017;9:214–221. Available from: http://jtd.amegroups.com/article/view/11602/9968
   PubMed Web of Science ®Google Scholar
• Almarzoky Abuhussain SS, Sutherland CA, Nicolau DP. Single β-lactams versus combinations as empiric therapy for infections with Pseudomonas aeruginosa: assessing the in vitro susceptibility. Infect Dis (Auckl). 2020 [cited 2020 Jun 23];52:33–38. Available from: https://pubmed.ncbi.nlm.nih.gov/31595829/
   PubMed Web of Science ®Google Scholar
• Castanheira M, Duncan LR, Mendes RE, et al. Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and enterobacteriaceae isolates collected from respiratory tract specimens of hospitalized patients in the United States during 2013 to 2015. Antimicrob Agents Chemother. 2017;62(3):e02125–17.
   Web of Science ®Google Scholar
• Sucher AJ, Chahine EB, Cogan P, et al. Ceftolozane/Tazobactam. Ann Pharmacother. 2015;49:1046–1056.
   PubMed Web of Science ®Google Scholar
• Escolà-Vergé L, Pigrau C, Los-Arcos I, et al. Ceftolozane/tazobactam for the treatment of XDR Pseudomonas aeruginosa infections. Infection. 2018;46:461–468.
   PubMed Web of Science ®Google Scholar
• Bradley JS, Ang JY, Arrieta AC, et al. Pharmacokinetics and safety of single intravenous doses of ceftolozane/tazobactam in children with proven or suspected gram-negative infection. Pediatr Infect Dis J. 2018;37:1130–1136. Available from: http://insights.ovid.com/crossref?an=00006454-201811000-00012
   PubMed Web of Science ®Google Scholar
• Lucasti C, Hershberger E, Miller B, et al. Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections. Antimicrob Agents Chemother. 2014;58:5350–5357.
   PubMed Web of Science ®Google Scholar
• Wagenlehner FM, Umeh O, Steenbergen J, et al. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet. 2015;385:1949–1956. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0140673614622200
   PubMed Web of Science ®Google Scholar
• Solomkin J, Hershberger E, Miller B, et al. Ceftolozane/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI). Clin Infect Dis. 2015;60:1462–1471.
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Chung P, Adam H, et al. Ceftolozane/tazobactam: A novel cephalosporin/beta-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli. Drugs. 2014;74:31–51.
   PubMed Web of Science ®Google Scholar
• Huntington JA, Sakoulas G, Umeh O, et al. Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial. J Antimicrob Chemother. 2016;71:2014–2021.
   PubMed Web of Science ®Google Scholar
• Castón JJ, Á DLT, Ruiz-Camps I, et al. Salvage therapy with ceftolozane-tazobactam for multidrug-resistant Pseudomonas aeruginosa infections. Antimicrob Agents Chemother. 2017;61. DOI: 10.1128/AAC.02136-16
   Google Scholar
• Bassetti M, Castaldo N, Cattelan A, et al. Ceftolozane/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience. Int J Antimicrob Agents. 2019;53:408–415. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0924857918303261
   PubMed Web of Science ®Google Scholar
• Fernández-Cruz A, Alba N, Semiglia-Chong MA, et al. A case-control study of real-life experience with ceftolozane-tazobactam in patients with hematologic malignancy and Pseudomonas aeruginosa infection. Antimicrob Agents Chemother. 2018;63:e02340–18.
   Web of Science ®Google Scholar
• Álvarez Lerma F, Muñoz Bermudez R, Grau S, et al. Ceftolozane-tazobactam for the treatment of ventilator-associated infections by colistin-resistant Pseudomonas aeruginosa. Rev Esp Quimioter. 2017;30:224–228. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28361526
   PubMed Web of Science ®Google Scholar
• Cabot G, Bruchmann S, Mulet X, et al. Pseudomonas aeruginosa Ceftolozane-Tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC. Antimicrob Agents Chemother. 2014;58:3091–3099.
   PubMed Web of Science ®Google Scholar
• Berrazeg M, Jeannot K, Ntsogo Enguéné VY, et al. Mutations in β-LACTAMASE AmpC increase resistance of Pseudomonas aeruginosa isolates to antipseudomonal cephalosporins. Antimicrob Agents Chemother. 2015;59:6248–6255.
   PubMed Web of Science ®Google Scholar
• Gelfand MS, Cleveland KO. Ceftolozane/tazobactam therapy of respiratory infections due to multidrug-resistant Pseudomonas aeruginosa. Clin Infect Dis. 2015;61:853–855.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Vena A, Castaldo N, et al. New antibiotics for ventilator-associated pneumonia. Curr Opin Infect Dis. 2018;31:177–186.
   PubMed Web of Science ®Google Scholar
• Galani I, Papoutsaki V, Karantani I, et al. In vitro activity of ceftolozane/tazobactam alone and in combination with amikacin against MDR/XDR Pseudomonas aeruginosa isolates from Greece. J Antimicrob Chemother. 2020. DOI:10.1093/jac/dkaa160/5843863
   PubMed Web of Science ®Google Scholar
• Grupper M, Sutherland C, Nicolau DP. Multicenter evaluation of ceftazidime-avibactam and ceftolozane-tazobactam inhibitory activity against meropenem-nonsusceptible Pseudomonas aeruginosa from blood, respiratory tract, and wounds. Antimicrob Agents Chemother. 2017;61:1–8.
   Web of Science ®Google Scholar
• Micek ST, Chew B, Hampton N, et al. A case-control study assessing the impact of nonventilated hospital-acquired pneumonia on patient outcomes. Chest. 2016;150:1008–1014.
   PubMed Web of Science ®Google Scholar